Evidence map›Paper›PMID 36398055›Full record

ArticleCurrent trends in immunology2022

The "Janus-like" RNA-editing machinery in innate antiviral immunity.

Lisa Wu, Denong Wang

Open access · greenAbstract read
In one paragraph

Article in Current trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lisa WuTumor Glycomics Laboratory, SRI International Biosciences, 333 Ravenswood Ave., Menlo Park, CA, USA.
Denong WangTumor Glycomics Laboratory, SRI International Biosciences, 333 Ravenswood Ave., Menlo Park, CA, USA.
SRI International · US

Funding

Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomasR21CA254048 · NCI · SRI INTERNATIONAL · PI WANG, DENONG · 2021 to 2022
$576k
ADAR1-Mediated HIV RNA ModificationsR21DA046144 · NIDA · SRI INTERNATIONAL · PI WANG, DENONG · 2018 to 2019
$561k
NCI NIH HHS R21 CA254048NIDA NIH HHS R21 DA046144
6 · The paper itself

Abstract

Our innate immune systems are evolved to provide the first line of immune defense against microbial infections. A key effector component is the adenosine deaminase acting on the RNA-1 (ADAR-1)/interferon (IFN) pathway of the innate cytoplasmic immunity that mounts rapid responses to many viral pathogens. As an RNA-editing enzyme, ADAR-1 targets viral RNA intermediates in the cytoplasmic compartment to interfere with the infection. However, ADAR-1 may also edit characteristic RNA structures of certain host genes, notably, the 5-hydroxytryptamine (serotonin) receptor 2C (5-HT

Indexed as

5-HT2CRADAR-1COVID-19interferonmeasles virusesRNA editingSARS-CoV-2substance use disordersSudemycin D6U87

Identifiers

PMID36398055
PMCPMC9668064
OpenAlexW4309665146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.